We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Neurology

Journal Scan / Research · October 21, 2021

QoL and Productivity Improvement With Fremanezumab After Poor Response to Other Migraine Prophylactics

Headache

 

Additional Info

Disclosure statements are available on the authors' profiles:

Headache
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
Headache 2021 Aug 10;[EPub Ahead of Print], ELH Spierings, X Ning, V Ramirez Campos, JM Cohen, S Barash, DC Buse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading